Halozyme Therapeutics Inc. (HALO) announced after the close Wednesday that the Center for Biologics Evaluation and Research of the FDA has issued a complete response letter for Baxter's HyQ Biologics License Application.
Halozyme Therapeutics gapped open dramatically lower Thursday, but traded in a narrow range throughout the session. Shares finished down by 4.26 at $4.30 on the highest volume of the year. The stock plunged to a new low for the year.
For comments and feedback: editorial@rttnews.com